DXCM

DXCM

USD

DexCom Inc. Common Stock

$61.180+0.090 (0.147%)

Preço em tempo real

Healthcare
Dispositivos médicos
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$61.090

Máximo

$62.390

Mínimo

$58.880

Volume

8.96M

Fundamentos da empresa

Capitalização de mercado

23.9B

Setor

Dispositivos médicos

País

United States

Estatísticas de negociação

Volume médio

5.54M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $56.45Atual $61.180Máximo $93.25

Relatório de análise de IA

Última atualização: 4/11/2025
Gerado por IAFonte de dados: Yahoo Finance, Bloomberg, SEC

DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?

Market Pulse Check

  • Current Price: $60.43 (as of 2025-11-03 close)
  • Recent Swing: +3.8% rebound after 61% decline since August highs
  • Key Technicals: MACD bearish crossover vs. surging 19x average volume

Price Action Breakdown

  • August-Sept Stability: Traded $75-$82 range
  • Sept 19 Crash: -11% drop on 3x average volume
  • October Freefall: 35% decline accelerated by legal news
  • November Lifeline: +3.8% gain on massive 17.8M shares traded

News Impact Matrix

SentimentCountKey Developments
Negative96 law firm investigations filed
Analyst Mixed128 lowered PTs (range $75-$99)
Positive1New board member appointment

AI Forecast Snapshot

TimeframePredictionNotes
1-day-0.8%Potential pullback after surge
2-day+1.6%Technical rebound potential
3-day+1.9%Resistance near $62 area

Strategic Considerations

For Active Traders:

  • Watch $61.15 breakout level (Nov 3 high)
  • Consider partial profits at $62.90 TP
  • Hard stop below $58.50 support

Long-term Investors:

  • Monitor lawsuit developments closely
  • Debt concerns (94% D/E ratio) require scrutiny
  • Potential accumulation zone if $58 holds

Bottom Line

DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.


This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.

Notícias relacionadas

PR Newswire

Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...

Ver mais
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Analyst Upgrades

UBS Maintains Buy on DexCom, Lowers Price Target to $95

UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.

Ver mais
UBS Maintains Buy on DexCom, Lowers Price Target to $95
Analyst Upgrades

Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82

Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.

Ver mais
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Analyst Upgrades

Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80

Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.

Ver mais
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
PR Newswire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...

Ver mais
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...

Analyst Upgrades

Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93

Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.

Previsão de IABeta

Recomendação de IA

Altista

Atualizado em: 4/11/2025, 21:09

BaixistaNeutroAltista

60.6% Confiança

Risco e negociação

Nível de risco3/5
Risco médio
Adequado para
AgressivoConservadorCrescimento
Guia de negociação

Ponto de entrada

$58.80

Tomar lucro

$62.91

Parar perda

$52.39

Fatores-chave

DMI mostra tendência de baixa (ADX:15.5, +DI:9.8, -DI:18.9), sugerindo cautela
O volume de negociação é 19.6x a média (59,957), indicando pressão de compra extremamente forte
MACD -0.1446 está abaixo da linha de sinal -0.0199, indicando um crossover de baixa

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.